The high wave will become a large player in the German medical center with the acquisition of shares in the Remexian Pharma GMBH
In the last 12 months, Remexian has income 65 million euros income
Remexian sold 7 tons of cannabis flower in the quarter of 2025, which is 43 tons of 16% imported to Germany in the quarter
Calgary, ABD, August 14, 2025 / PRNEWSWIRE / – High Tide Inc. (“High Termosity” or “Company”) (NASDAQ. HITI) (FSE: PHARMA GMBH (“Remexian”), 27.2 million euros (“transaction”) and will have an option to obtain the rest of interest in Remexia.
It was founded in 2018. Among the buyers of all Germany’s doctors, Remexian has one of the most popular in the world, which is currently licensed from 19 countries, including Canada, who represents about 33% of their total imports to Germany. Taking into account more than $ 1.9 billion from Canadian Canadian sales, a high channel has a Canadian shopping expertise and relationships to make this transaction significantly increase the Canadian Canadian department in Germany.
“Remexian is ideal for us, not only prices, but also with its operational approach, which prevents the highest price team. Said Raj Grover, the founder and CEO of the High Channel.
“With this high-quality acquisition, it’s about $ 100 million to significant EBITDA, we will talk about more affordable prices, which are imported to the highest quality brands,” Mr. Gurverer added.
“We are truly energy with a strong certigion that we have found with a high wave, the impressive scale of which enhances our influence in Germany,” said Remexyan co-founder Marcus Wenner. “Our two companies have deliberately have a strategic approach to becoming leaders in our relevant markets.
In April 2024, the demand for medical cannabis continued to accelerate in the country since the adoption of the German consumer Act of Germany. Over the past year, the number of medical cannabis has sharply increased by 250,000 to about 900,000 to 1 billion euros (BFAMM). 2025 (37.5 tons) and twelve months roll in total 134 tons, maintaining its place as the world’s largest medical importer. The growth of demand has also stimulated the position of Canada as a leading global exporter, the country’s German imports, about 36 tons in the first six months of 2025.
The Remexian, led by Francesco Baghan and Stefan Adome, is a leader in German Medical Cannabis, with an annual income, and 43 tons of 16 million euros and 15 million euros and a quarterly imported in Germany.
When the acquisition concluded, the company considered the potential of changes in Germany’s medical cannabis. The company believes that even if the restrictions are posted on telemedicine and postpone, which is subject to a long-term legislative review, the market will continue to grow after the adjustment period.
___________________________
Alcalculation agreements based on REMEX sales data and import numbers, which were publicly released by BFARM.
Oursource. War of flowers’ prices. German boom, the reality of Great Britain
³SOURCE: BFARM (Q2 2025 Update)
Alcalculation agreements based on REMEX sales data and import numbers, which were publicly released by BFARM.
Deal details
The transaction is subject to the wing length of time, among other things, it is necessary to exchange TSX enterprise (“TSXV”) and other customs conditions and are expected to be closed in the coming weeks. This implies a 53.4 million euros app that represents the 3,64065 times an annual Ebitda, which was created in six months of March 31, 2025, and is subject to certain adjustments based on working capital and closure. For 51% of the acquired equality, the preliminary estimated price of 27.2 million euros will be satisfied as follows:
42% of high-tidal tidal shares (“Ri-High Shares”) Price in US $ 2.1912, presenting the average average price for NASDAQ for NASDAQ.
29% cash.
29% of loans from sellers (“Credit”). The loan will ripen on December 31, 2029, annual annual interests (paid quarterly) will lead to a pre-payment company without penalty.
In addition to the above, the Remexian owners agreed to provide a high-channel option that acquires the remaining interests remaining in the Remexian through high tidal tide (“Call version”). The call option will be implemented at any time for a five (5) years of closing twenty four (24) monthly anniversary (“term” of the call version). The call option is carried out for the value of the enterprise, which is equal to the 12th Tebit Date of the Adjusted EBITDA, if the call version is performed in the first twelve (12) month of the call version. In addition, the high channel agreed to provide Remember owners to reset the remaining interests in high tidal lecture. Taking into account the option or set version, given the case, it will be satisfied with the Cash and High Combination Character at the discretion of the high wave. The call option has a minimum price of 15 million euros, and is subject to at least 40% of the payment of minimum cash, and the installed version is subject to at least 30% cash.
Any high levels related to the transaction are subject to four months and one day of stateration.
About a high wave
High Tide, Inc. is a leading community, retail Cannabis, developed to unleash the full cost of the world’s most powerful factory. The whole subsidiary of it, Canna Kabana, is the second largest brand of Cannabis in the world. High wave (HITI) is unique around cannabis consumer, fully diversified and fully integrated with all components of cannabis, including:
Bricks & Mortar Retail. Canna CABANA is Canada’s largest retail network in Canada, 203 Current places that pass through British Columbia, Alberta, Saskakateva, Manitoba, Ontario. In 2021, Kanina Cabana became the retail sale of the Cannabis Discount Club in the world.
Retail innovation. Fastendr ում is a unique and fully automated technology that uses retail kiosks to facilitate better purchase experience with observation, order and pickup.
Consumption accessories. The high wave operates the world’s leading e-commerce platforms, including grasscity.com, Smokecartel.com, DailyHighclub.com and Dankstop.com.
Brands. The list of HIGH Wave Industry and Consumer Brand includes Bud ™, Daily High Club Wea, Daily High Club ™, Vodka Glass Pass ™, Donezilla ™, Atomik ™ etc.
CBD. High channel continues to develop consumer CBD capabilities via Nuleafnaturals.com, fabcbd.de and brabscbd.co.uk.
Wholesale distribution. The high wave keeps the category of cannabis through wholesale solutions through Valiant.
Licensing. The high channel continues to push the culture of Cannabis through fresh partnership and license agreements under the name of the famous brandz.
The high tide is consistently moving forward before the fourth year in a row was named one of the best growing companies in Canada in 2024, as well as for the fastest growing companies in 1023. Tide, visit www.hightideinc.com. Do not miss high pages of high tidal tide in Sedan and Edgar for investment.
NCV NewsWire aims to treat high-quality content and information about cannabis companies by New Cannabis Ventures to help our readers make noise and remain the most important cannabical business news. NCV Newswire is hand treated by hand and is not automated. Have secret news tip. Contact:A number
Statistics Canada has released February retail sales for the country, with Cannabis sales are declining from January levels, down 7.9% from the previous month to C$440.5 million. The sequential decrease increased by 2.0% on a daily basis due to fewer days than in the previous month. January, originally reported at C$466.1 million, was revised higher to C$478.2 million. February sales rose 7.9% from a year ago, down 9.4% from last month, and 8.3% in May and 7.5% in June, but better than last year’s slowest growth rate since legalization -0.9% in September 2024 due to the BC strike. Total sales are expected to increase by 4.5% to C$5.39 billion in 2024 and by 4.1% to C$5.62 billion in 2025. So far in 2026, sales are up 8.6%.
An increase in the number of shops, as well as a fall in the prices of flowers that attract consumers from the illegal market, have boosted sales. In Ontario, the most populous province, sales fell 11.4% from January and 3% from a year ago. Alberta was down 10.2% from January, but up 1% from a year ago. British Columbia was up 3.7% from January and up 33% from a year ago, while Quebec was down 9.6% from January but up 30% from a year ago.
March sales data will be released on May 22.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Aurora Cannabis accelerates global medical cannabis leadership with proactive acquisition of Safari Flower, expanding EU GMP capabilities to serve growing high-margin international markets.
EDMONTON, AB, April 15, 2026. /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, is pleased to announce that it has acquired Safari Flower, an EU GMP certified cannabis developer and manufacturer. The aggregate consideration is valued at $26.5 million, subject to customary adjustments and including a $2 million cash payment contingent on the satisfaction of certain conditions (the “Deal”).
“The acquisition of Safari Flower is an important milestone for Aurora as we continue to make targeted investments in expanding our EU GMP capabilities to support the rapidly growing international medical cannabis market. The expanded supply chain will enable us to capture greater international market share while delivering superior quality and value to our most valued patients around the world,” said Miguel Martin, Aurora’s Executive Chairman and Chief Executive Officer.
Strategic rationale
Safari Flower Company’s 59,000-square-foot, purpose-built EU GMP certified in-house processing and manufacturing facility in Ontario, Canada will provide the company with increased capacity that closely aligns with its existing cultivation and manufacturing facilities.
The increased capacity will be used to supply EU GMP flower to Aurora’s key international markets, including Germany, Australia, Poland and the UK, and will support further market expansion.
This transaction is expected to result in a positive adjusted EBITDA contribution in fiscal year 2027, with additional benefits in fiscal year 2028 and beyond as these assets are optimized in the Company’s supply chain.
Aurora intends to leverage its plant science and operational expertise to drive operational efficiencies, improve crop yields and support high-margin commercialization in international markets.
Transaction details
Aurora, through a wholly-owned subsidiary, has indirectly purchased 100% of the shares of 9869247 Canada Limited (“Safari Flower Company”) for an aggregate consideration of $26.5 million, including a cash payment of $2 million subject to the satisfaction of certain conditions. As closing consideration, Aurora (i) issued to the selling stockholder 2,417,180 shares of common stock; and (ii) paid the selling stockholder $15 million in cash, subject to customary post-closing adjustments.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets in Canada, Europe, Australia and New Zealand with a strategic focus on high margin opportunities and a medical first approach. Aurora’s portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products to open up the world to cannabis.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora common stock trades on the NASDAQ and TSX exchanges under the symbol “ACB”.
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not automated in any way. Got a secret news tip? Get in touch.
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
Just before Christmas, this newsletter discussed how Vireo Growth is getting pretty big. At the end of January I profiled how Vireo Growth is expanding its business. This week’s newsletters include six articles we’ve run since April 2, and Vireo Growth is central to two of them. Vireo Growth is big and getting bigger, but few people seem to care.
I’m not writing this to tell readers to care. In fact, while I used to include the company on my Focus List at 420 Investor, I no longer do. Earlier this month I wrote an article for my subscribers about why I keep looking at things but not including stocks in my Focus List. Here is the summary.
I watch VREOF because it is now one of the largest MSOs by revenue, but it continues to fall short of joining the Global Hemp Stock Index due to its low trading volumes. Average daily trading volume over the past month was 251,000 shares, which is about $100,000 in daily trading value. This is well below peers. Perhaps more importantly, the current price of $0.45, which is down 26.6% year-to-date, is significantly lower than the price of $0.625 for the last large cap in 2024. Not only are the investors not winning, but VREOF hsa distributed a lot of shares to the sellers and they are also under water.
Maybe Vireo Growth shares will reward their owners, or maybe it will continue to do so. I think hemp stock investors and debt holders should be asking why no one is thinking of this yet. Scotts Miracle-Gro, which has been public since 1992 and has a market cap of $3.6 billion, picked up much of VREOF’s stock when it spun off Hawthorne. The 213 million shares are “at an implied price of $0.60” per share, although VREOF hasn’t traded at $0.60 since January. When the divestiture was announced in late January, Vireo Growth closed at $0.5553.
So a large MSO that has reshuffled its management, is now in multiple markets, and has executed its plan to get bigger with several acquisitions, is still not responding to the cannabis investment community. I wish them the best.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
